Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 6 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days
Taiho Pharmaceutical Co., Ltd. maintains a portfolio with 11 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are spread across 6 distinct art units, indicating a broad research and development focus within the life sciences sector. The prosecution involves 10 distinct examiners, which requires the company to manage a variety of examination styles and requirements simultaneously.
The busiest examiner for this portfolio is FETTEROLF, BRANDON J, who is currently handling 2 pending office actions. This is the only examiner with more than a single case, as the remaining pending actions are distributed among different examiners. This high level of examiner diversity means that the company's success is not tied to any individual's interpretation of patent law.
With 11 pending actions and 10 examiners, the prosecution strategy must be highly adaptable. The presence of 6 distinct art units suggests that the pharmaceutical innovations being protected cover a range of specific biological or chemical classifications. Practitioners should monitor the 2 actions under FETTEROLF, BRANDON J for potential trends while remaining prepared for unique challenges in the other cases.
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (8%) |
| §112 only | 4 (33%) |
| Double-patenting + other | 3 (25%) |
| Multi-statute (no §101) | 4 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 2 | 52.0% | +17.4% |
| PURDY, KYLE A | 1 | 41.0% | +35.9% |
| BRAUN, MADELINE E | 1 | 68.0% | +25.7% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.7% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| HERNANDEZ, JACKSON J | 1 | 51.4% | +45.0% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.7% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 3d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 9d |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 22d |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 23d |
| 18704901 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | KOSAR, ANDREW D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | HERNANDEZ, JACKSON J | 238d overdue |
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 88d overdue |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 3d overdue |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 9d |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 15d |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 23d |
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | PURDY, KYLE A | — |
| 18713496 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | BRAUN, MADELINE E | — |
| Art Unit | Apps |
|---|---|
| 1626 | 3 |
| 1624 | 2 |
| 1628 | 2 |
| 1629 | 1 |
| 1627 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18873090 | PHARMACEUTICAL COMPOSITION CONTAINING PIMITESPIB | PURDY, KYLE A | — | §103 | Non-Final OA | — | Pending | Dec 09, 2024 |
| 18713496 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | BRAUN, MADELINE E | 1624 | §102§103§112DP | Non-Final OA | — | Pending | May 24, 2024 |
| 18704901 | PROCESS FOR PREPARING A BENZOATE SALT OF A 1-(3-AMINOPYRROLIDINE-1-CARBONYL)-3,4-DIPHENYLBENZENE COMPOUND | KOSAR, ANDREW D | — | §103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18563058 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | FETTEROLF, BRANDON J | 1626 | §102§103Other | Non-Final OA | 9d | Pending | Nov 21, 2023 |
| 18253521 | Crystalline Forms of 4-amino-N-[4-(methoxymethyl)phenyl]-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide, Methods of Preparation, and uses Thereof | FETTEROLF, BRANDON J | 1626 | §112 | Non-Final OA | 15d | Pending | May 18, 2023 |
| 18253229 | Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102DPOther | Final Rejection | — | Pending | May 17, 2023 |
| 18026515 | METHODS OF TREATING RIBONUCLEOTIDE REDUCTASE-RELATED DISEASES WITH A RIBONUCLEOTIDE REDUCTASE INHIBITOR | RODRIGUEZ, RAYNA B | 1628 | §103§112Other | Final Rejection | 23d | Pending | Mar 15, 2023 |
| 18015616 | PYRIMIDINE COMPOUND-CONTAINING COMBINATION TO BE USED IN TUMOR TREATMENT | HERNANDEZ, JACKSON J | 1627 | §112Other | Non-Final OA | 238d overdue | Pending | Jan 11, 2023 |
| 17788847 | AGENT FOR ADJUVANT THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Non-Final OA | 88d overdue | Pending | Jun 24, 2022 |
| 17786504 | THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT | WILLIS, DOUGLAS M | 1624 | §112 | Non-Final OA | 3d overdue | Pending | Jun 16, 2022 |
| 17432158 | PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR | COPPINS, JANET L | 1628 | §112 | Final Rejection | — | Pending | Aug 19, 2021 |
| 16627146 | CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND | MCKOY, QUINCY ANDRE | 1626 | §103§112Other | Final Rejection | 22d | Pending | Dec 27, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial